Navigation Links
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
Date:3/2/2009

Highly Statistically Significant Results Achieved at Two Dose Levels with No Reversal of Analgesia

SAN CARLOS, Calif., March 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced positive topline results today from a Phase 2 double-blind, randomized, placebo-controlled study of NKTR-118 in patients with opioid-induced constipation (OIC). NKTR-118, a peripheral opioid antagonist, is an oral once-a-day investigational drug to treat OIC, the most common and debilitating manifestation of opioid-bowel dysfunction (OBD). The Phase 2 study of NKTR-118 is terminating early on the basis of overwhelming evidence of efficacy at two different dose levels of 25 mg once daily and 50 mg once daily. The study achieved a clinically meaningful and highly statistically significant, dose-dependent increase in spontaneous bowel movements (SBMs) from baseline after the first week of NKTR-118 treatment with the 25 mg dose and the 50 mg dose versus placebo (p < 0.01 for all comparisons). Patients receiving the 25 mg dose of NKTR-118 had an average of 5.1 SBMs during the first week of treatment as compared to 1.5 SBMs per week during the baseline period. Patients receiving the 50 mg dose of NKTR-118 had an average of 5.7 SBMs during the first week of treatment versus 1.6 SBMs per week during the baseline period. The increase in SBMs versus placebo was maintained over the 28-day treatment period (p <0.01). More importantly, in the 25 mg and 50 mg dose cohorts, there was no reversal of analgesia as measured by a change in pain Numerical Rating Scale (NRS) and no increase in opiate use.

"These data show that NKTR-118 taken orally once-daily at the 25 mg and 50 mg dose levels dramatically increased bowel movements within the first week of treatment for patients with OIC," said Lynn R. Webster, M.D., Medical Director, Lifetre
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
2. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
3. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
5. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
8. TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
9. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
10. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced ... for use in portable vaporizers, which contains CBD, ... in cannabis, cannabidiol offers consumers a THC-free product ... other vaporizer technology. Photo - ... 483 different compounds which are currently known, two ...
(Date:7/11/2014)... , July 11, 2014 Patient engagement ... and, consequently, organizations are turning to an assortment ... As part of this evolving approach to ... educate, communicate and engage patients throughout their experiences ... patient empowerment. By mapping the patient journey and ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
(Date:7/13/2014)... (PRWEB) July 13, 2014 According ... Processing and Computing Market by Component (processor, GPU, ... Automotive, MDA, Medical), and Geography - Forecast and ... Heterogeneous Mobile Processing & Computing Market is expected ... a CAGR of 20.75% from 2014 to 2020. ...
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... New York, New York (PRWEB) July 13, 2014 ... much to bring attention to the cancer risks associated ... a chance to tell their story to federal regulators, ... of a U.S. Food & Drug Administration (FDA) ... Liebhard LLP reports. According to the Rochester Democrat ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... type of sensor for people with diabetes is being developed ... of blood, researchers report. Scientists at Brown University in ... artificial saliva. It uses light, metal and a special enzyme ... knows that diabetics have to prick their fingers to draw ...
(Date:7/13/2014)... TX (PRWEB) July 13, 2014 The Pearland, ... children ranging in age from four months to 12 years ... and karate classes to birthday parties and Summer Camps, is ... Little Gym of Pearland after spending over six ... of roles, including Gym Director. , Berry has over ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2
... WEST CONSHOHOCKEN, Pa., May 1 Cadient Group, ... announced today it has appointed Barbara Dowling as ... in the healthcare,vertical on both the client and ... the digital channel to address business critical,issues. In ...
... Inc. (TSX: DDS;,NASDAQ: DDSS) today announced the dates and ... and Annual Meeting of Shareholders., First Quarter Results ... a.m. (ET) Labopharm will host a conference,call to discuss ... first quarter 2008 financial results via news release at,approximately ...
... (Nasdaq: GTIV ), the nation,s leading provider of,comprehensive home ... quarter ended March 30, 2008:, (Logo: ... to $323.7 million versus the first quarter ... 13% to $7.7 million, or $0.27 per diluted share, ...
... intensive care will experience delusions or hallucinations, which put ... to a new study of childrens experiences in a ... which appears in the first issue for May of ... published by the American Thoracic Society, is believed to ...
... may also mask its severity in standard tests, according to ... women with a range of body mass indexes (BMIs). , ... comparative difference in how the airways and lungs respond to ... , The research is reported in the first issue for ...
... Christopher,s Hospital for Children and Independence Blue,Cross (IBC) ... principle,on terms of new contracts. They have extended ... multi-year contracts. Hahnemann and St.,Christopher,s are both part ... network of hospitals. The parties will continue to ...
Cached Medicine News:Health News:Cadient Group Appoints Barbara Dowling to Senior Vice President Customer Engagements 2Health News:Labopharm announces details for first quarter results conference call and annual meeting 2Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 2Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 3Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 4Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 5Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 6Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 7Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 8Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 9Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 10Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 11Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 12Health News:Haunted by hallucinations: Children in the PICU traumatized by delusions 2Health News:Obesity worsens impact of asthma 2Health News:Hahnemann University Hospital and St. Christopher's Hospital for Children Extend Current Agreement With Independence Blue Cross 2Health News:Hahnemann University Hospital and St. Christopher's Hospital for Children Extend Current Agreement With Independence Blue Cross 3
... simplified focusing guidance system has ... to use of its type. Technicians ... LM-770 with a minimum of instruction. ... target lines to focus first. A ...
... is the newest generation of electronic refractors. The ... control the refractor from a keypad that is small ... controls the CP-670 Automatic Chart Projector. The TRS is ... all the lenses are moved for you, taking you ...
The Electric H-Base Table is for heavier instruments, or for those who prefer electric elevation. The electric table easily accepts a slit lamp, a single tabletop, or a double tabletop, just as the M...
The Manual Table Base is elevated with an easy to reach elevating wheel for smooth operation. The table base will accept a slit lamp, a single table top, or a double tabletop for more than one instru...
Medicine Products: